The growth, survival, and metabolic activities of multicellular organisms at the cellular level are regulated by intracellular signaling, systemic homeostasis and the pericellular microenvironment. Pericellular proteolysis has a crucial role in processing bioactive molecules in the microenvironment and thereby has profound effects on cellular functions. Hepatocyte growth factor activator inhibitor type 1 (HAI-1) and HAI-2 are type I transmembrane serine protease inhibitors expressed by most epithelial cells. They regulate the pericellular activities of circulating hepatocyte growth factor activator and cellular type II transmembrane serine proteases (TTSPs), proteases required for the activation of hepatocyte growth factor (HGF)/scatter factor (SF). Activated HGF/SF transduces pleiotropic signals through its receptor tyrosine kinase, MET (coded by the protooncogene MET), which are necessary for cellular migration, survival, growth and triggering stem cells for accelerated healing. HAI-1 and HAI-2 are also required for normal epithelial functions through regulation of TTSP-mediated activation of other proteases and protease-activated receptor 2, and also through suppressing excess degradation of epithelial junctional proteins. This review summarizes current knowledge regarding the mechanism of pericellular HGF/SF activation and highlights emerging roles of HAIs in epithelial development and integrity, as well as tumorigenesis and progression of transformed epithelial cells.
In higher organisms, tissues are constituted by numerous types of differentiated cells. To maintain homeostasis, all cells must be integrated into an architectural and signaling framework and respond to commands appropriate for environmental and systemic demands. In this process, interactions between cells and between cells and surrounding stroma are critical. Failure of the process results in a spectrum of dysfunctions, such as abnormal development, persistent inflammation, delayed regeneration and even neoplastic tumor formation. In the extracellular milieu, proteolysis is an essential post-translational system to regulate the fate of proteins. Pericellular proteolysis is required for turnover and remodeling of the extracellular matrix as well as activation or processing of other zymogens, growth factors and protease-activated receptors (PARs). Consequently, proteolysis has considerable influence on the outside-in signaling required for cellular homeostasis, responses to injury and regeneration. 1 Dysregulated proteolysis is observed in diseased tissues, including tumors, and sometimes, it is a causal factor of the disease. [1] [2] [3] This review highlights a recently emerging system of serine proteases/protease inhibitors that play critical roles in epithelial integrity and regeneration. This system also influences tumorigenesis and cancer progression of epithelial tissues. We first describe pericellular proteolytic activation of peptide growth factors, with a focus on hepatocyte growth factor (HGF)/scatter factor (SF) and its physiological and pathological significance. Next, we briefly review recent data regarding specific proteases, HGF activator (HGFA) and type II transmembrane serine protease (TTSP) that are involved in the activation of HGF/SF. Then, we describe the regulation of these proteases by membrane-anchored serine protease inhibitors, namely HGFA inhibitor type 1 (HAI-1)/serine peptidase inhibitor, Kunitz type 1 (SPINT1) and HAI-2/SPINT2, and their emerging roles in epithelial integrity, regeneration and malignant progression of epithelial cells.
PROTEOLYTIC ACTIVATION OF HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR (HGF/SF) IN THE PERICELLULAR MICROENVIRONMENT
One example of a growth factor that is critically regulated by extracellular proteolysis is HGF/SF. HGF/SF is a typical paracrine factor secreted by stromal cells. 4 It transduces signals through the MET receptor, a receptor tyrosine kinase (RTK) that is expressed broadly in epithelial, endothelial and cancer cells. 5 In some cancer cells, an autocrine HGF/SF-MET circuit is present. [6] [7] [8] Binding of HGF/SF to MET transduces pleiotropic signals required for cellular growth, escape from apoptosis and migration. 5, 8 Ample evidence has accumulated for the crucial roles of HGF/SF-MET signaling in the development and regeneration of injured tissue and invasive growth of cancer cells. Global knockout of HGF/SF in mice results in embryonic lethality due to impaired placental development. 9 Hepatocytes are the best known targets of HGF/SF. Nonetheless, most epithelial cells and non-epithelial cells that express MET respond to HGF/SF, 4 and tissue stem cells also utilize HGF/SF-MET signaling for their in vivo functions. 10 HGF/SF is a member of the kringle domain protein family, showing a molecular structure homologous to plasminogen. 4 Similar to plasminogen, HGF/SF is secreted as an inactive proform (proHGF/SF). Therefore, activation by limited proteolysis of proHGF/SF is critically required to transduce signaling through the MET receptor. 2, 4 Several proteases are reportedly responsible for the activation of proHGF/SF. It should be emphasized that despite the similarity of molecular structures between proHGF/SF and plasminogen, tissue-and urokinase-type plasminogen activators (tPA and uPA) do not activate proHGF/SF in physiological settings. 2, 11 At present, the proHGF/SFactivating proteases are categorized into two groups: (i) circulating activators and (ii) local cell surface activators (Table 1) . 12 The most efficient circulating activator is HGFA. [13] [14] [15] Moreover, HGFA is a primary activator of plasma macrophage stimulating protein (MSP) that is a ligand of RON (Recepteur d'origine nantais) RTK. 16 On the other hand, the cell surface activators of HGF/SF are TTSPs. Among the family of HGF/SF-activating TTSPs, matriptase and hepsin are the most efficient at activating proHGF/SF (Table 1) . 11, 12 Both are widely expressed in epithelial tissues and there is increasing evidence that they are involved in epithelial function, carcinogenesis and cancer progression.
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HGFA, A KEY MOLECULE OF HGF/SF ACTIVATION AT THE SITE OF TISSUE INJURY
HGFA is primarily synthesized and secreted by the liver and circulates as an inactive zymogen (proHGFA). It is a relatively abundant plasma protein with a concentration around 40 nM in healthy individuals. 15, 17 In fact, $70 mg of pro-HGFA was purified from 190 mL of human plasma.
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The purified proHGFA migrates with a molecular mass of around 98 kDa in SDS-PAGE under reducing condition. The human proHGFA gene (HGFAC) is located at 4p16, and the 5 0 -regulatory region of the gene lacks TATA and CAAT boxes but has several potential binding sites for known transcription factors including SP-1, AP-2, E2A, ETS, hepatocyte nuclear factor I and nuclear factor kB (NF-kB).
19
The murine Hgfac gene has a genomic structure and regulatory region similar to the human HGFAC gene. 20 It is noteworthy that the hepatic expression of HGFA mRNA was upregulated in response to extrahepatic tissue injury and the resulting inflammatory response at the site of tissue injury. 21 As local inflammation also stimulates the synthesis of proHGF/SF in systemic organs via humoral factors, 4, 22 tissue injury would result in concomitant upregulation of the circulating proHGFA and tissue proHGF/SF levels. ProHGFA belongs to the kringle domain protein family having a molecular structure homologous to coagulation factor XII. 14, 19, 23 To gain protease activity, proHGFA must be cleaved at the Arg407-Ile408 bond by limited proteolysis, and thrombin, kallikrein-related peptidase (KLK) 4 and KLK5 have been proposed as activators of proHGFA (Fig. 1a) . 18, 24, 25 Among them, thrombin is the most likely processing protease for proHGFA at the site of tissue injury. Indeed, considerable activation of HGFA occurs in injured tissues in vivo, where the blood coagulation cascade is activated, accompanying significant processing of proHGF/SF to its active two-chain form. 15, 22 Therefore, serum, but not plasma, shows substantial HGF/SF-activating activity, and we found that the proHGF/SF-processing activity of serum was abrogated in the sera from Hgfac knockout mice. 26 Together with the fact that the known HGFA substrates (proHGF/SF and proMSP) show structural similarities to plasminogen, 4, 15, 27 it is likely that the HGFA-HGF/SF system has an evolutionary history similar to the Values in parenthesis are the relative activity in the presence of high-molecular weight dextran sulfate.
NA, not applicable blood coagulation/fibrinolysis system. Indeed, the phylogeny of the cDNA sequences indicates that the gene for factor XII evolved from duplication of the gene encoding HGFA. 28 Furthermore, HGF/SF, MSP and plasminogen are likely derived from a common ancestral gene (Fig. 1b) . 28 Several lines of evidence indicate that HGFA is a primary activator of HGF/SF at the site of tissue injury and is required for the subsequent regenerating process. After CCl 4 -induced liver injury in rats, the expression of Hgfac mRNA was markedly enhanced in hepatocytes. This was accompanied by enhanced activation of HGF/SF in the injured liver tissue, which was inhibited by an anti-HGFA neutralizing antibody. 22 The anti-HGFA neutralizing antibody was also effective at suppressing robust activation of HGF/SF in human cancer tissue extracts. 29 In a mouse acute colitis models, both the activation of HGF/SF and initial epithelial reconstitution after ulcerative injury of the mucosa were significantly impaired in Hgfac knockout mice (Fig. 1c) . 26 In accordance with this finding, immunohisto- (Fig. 1a) . 10, 32 Whereas this observation was made in striated muscle stem cells and fibro-adipogenic progenitors, other somatic stem cells such as mesenchymal, epidermal and hematopoietic stem cells also express MET, [33] [34] [35] and accordingly, these stem cells may respond to HGFA in a similar fashion.
TTSPS: LOCALIZED CELLULAR ACTIVATORS OF HGF/SF IN EPITHELIAL TISSUES AND CANCERS
In addition to the tissue injury-induced activation machinery described above, a more localized system for HGF/SF activation is also required to maintain normal development and tissue homeostasis. In fact, whereas HGF/SF-null mice were embryonic lethal, 9 Hgfac À/À mice were normal at ) and HGFA-deficient (Hgfac À/À ) mice 2 days after acetic acid-induced ulcerating injury. 26 Note that epithelial restitution on the ulcer surface is significantly delayed in Hgfac À/À mouse. Bar, 50 mm.
birth, 26 indicating the existence of another physiological activation system for HGF/SF. Moreover, even in pathological conditions, localized machinery for pericellular HGF/SF activation is needed. For example, invading cancer cells require outside-in signals mediated by autocrine and paracrine HGF/SF for motility and survival. 5, 8 HGF/SF-induced paracrine signaling via MET is also necessary to maintain cancer stem cells, a pathway that contributes to drug resistance. 5, [36] [37] [38] In this context, there is rapidly accumulating evidence that TTSPs are critical components of cell surface machinery for activation of HGF/SF in the pericellular microenvironment. 3, 12 TTSPs are a recently emerging large family of membrane-anchored proteases ( Fig. 2 ) and include 17 serine proteases in humans ( Table 2) . 39 All
TTSPs have a single-pass transmembrane domain near the N-terminus. The intracellular domain is short except for TMPRSS13. The extracellular portion contains a conserved serine protease domain with a cleavage preference for substrates with Arg or Lys in the P1 position ( Fig. 2) . 39 In addition to TTSP, type I transmembrane protease (typrtase-ɤ1) and glycosylphosphatidylinositol (GPI)-anchored proteases (prostasin and testisin) are known as membraneanchored serine proteases, and interactions among these proteases are present (Fig. 2) . One example of this interplay is the interaction between matriptase (TTSP) and prostasin (GPI-anchored). Matriptase activates prostasin, and the latter is required for the activation and normal subcellular localization of matriptase. 40, 41 Prostasin is known to activate the epithelial sodium channel (ENaC), 39 and in consequence, this interplay may have a role in the ion transport system of epithelial cells. Several TTSPs have been shown to activate proHGF/SF, all of which are expressed by epithelial cells. 11, 39, 42, 43 Among them, matriptase shows the most efficient proHGF/SF processing activity (Table 1) . Matriptase is expressed by most epithelial cells in the body and is frequently upregulated in cancer cells. 3, 39 It also activates other RTK ligands such as MSP and platelet-derived growth factor (PDGF)-C and -D, as well as uPA and PAR-2 (Table 2) . 2, 39, 44, 45 Hepsin is another efficient cellular activator of HGF/SF. 11 It is expressed in the liver, kidney and some other epithelial tissues (Table 2 ) and is reported to be involved in the progression of prostatic, renal, gastric, ovarian, and breast cancers. 3, [46] [47] [48] Meanwhile, matriptase and hepsin cleave the extracellular domains of various RTKs, such as epidermal growth factor receptor (EGFR), Her2, insulin receptor, insulin-like growth factor-1 receptor, and PDGFR. 49, 50 Of particular interest is the observation that the amino-terminally truncated fragments of EGFR produced by matriptase cleavage were tyrosine phosphorylated and transduced signals. 49 The cleavage of tyrosine phosphorylated Her2 by matriptase resulted in a phosphorylated amino-terminally truncated fragment of Her2 that cannot be recognized by trastuzumab (Herceptin), which might be a potentially new mechanism of Herceptin resistance. 50 Taken altogether, dysregulated pericellular activities of TTSP may lead to uncontrolled RTK signaling and unexpected outcomes in epithelial cells and cancer cells.
REGULATION OF HGFA AND TTSP BY MEMBRANE-ANCHORED SERINE PROTEASE INHIBITORS, HAIS
HAI-1/SPINT1 (encoded by the SPINT1 gene: 15q15.1) and HAI-2/SPINT2 (SPINT2: 19q13.2) were initially identified in culture supernatants of the MKN45 human gastric cancer cell line. 51, 52 They were characterized as inhibitors of HGFA and hence named, "Hepatocyte growth factor Activator Inhibitor (HAI)." HAI-2/SPINT2 was also independently purified as a double Kunitz-type serine protease inhibitor abundantly expressed in the placenta, and termed "placental bikunin". 53 Although each HAI was purified from culture supernatant as a soluble protein, cDNA cloning revealed that they are both type I transmembrane proteins. 51, 52 They have two extracellular Kunitz-type serine proteinase inhibitor domains (KD1 and KD2), a single-pass transmembrane domain near the carboxyl terminus and a short intracytoplasmic domain (Fig. 3a) . Thus, the initially isolated soluble HAIs were cleaved fragments of the extracellular portion that retained inhibitor domains. In addition, the amino-terminus of HAI-1/SPINT1 has an N-terminus with an 8 cysteine (MANEC) domain and a polycystic kidney disease (PKD)-like domain, as well as a low density lipoprotein (LDL)-receptor class A domain between KD1 and KD2 (Fig. 3a) . In contrast, HAI-2/SPINT2 lacks these extra-domains. Two major splicing variants (isoforms a and b) are known for HAI-2/SPINT2, and the isoform b lacks KD1. However, the isoform b shows equal HGFA-inhibitory activity to the isoform a. 54 In in vitro assays, HAIs have relatively broad inhibitory spectra towards trypsin-like serine proteases and can inhibit all the proHGF/SF-activating TTSPs. However, their in vivo functions in both physiological and pathological settings are not fully understood, especially HAI-2/SPINT2. Using surgically resected human tissue specimens, cultured cells and genetically engineered mice, we have elucidated the physiological and pathological roles of HAIs. Whereas both HAIs were initially discovered as endogenous cellular inhibitors of HGFA, only HAI-1/SPINT1 was able to trap and inhibit activated HGFA on the cell surface. 55 In accordance with this finding, HAI-1 immunoreactivity is observed primarily on the cell surface and HAI-2 is detected intracellularly (Fig. 3b) . The HAI-1/SPINT1-HGFA complex was released from the cell surface by a metalloproteasemediated ectodomain shedding of HAI-1/SPINT1, which was induced by protein kinase C activation or inflammatory stimuli. 55 The inhibition of HGFA by HAI-1/SPINT1 is mediated by KD1 and reversible, and the shedding-form having both KDs (Fig. 3a) shows much lower affinity to HGFA compared with the membrane-anchored HAI-1/SPINT1. 15, 23 Therefore, after shedding, free active HGFA reappeared in the pericellular microenvironment where it activated pericellular HGF/SF. 55 These findings provide a novel model of protease/anti-protease interaction on the cell surface and pericellular microenvironment. That is, HAI-1/SPINT1 acts not only as an inhibitor but also as a reservoir of active HGFA to ensure sustained pericellular proHGF/SF activation. 55 On the other hand, in the past decade, evidence has amassed supporting critical functions of both HAIs to (Fig. 3c) . Interestingly, the type of HAI required for the proper matriptase trafficking is cell-type dependent. 41, [56] [57] [58] For example, whereas co-expression of matriptase with either HAI-1/SPINT1 or HAI-2/SPINT2 is sufficient for the cell surface localization of matriptase in HEK293 cells (Fig. 3c) , HAI-2/SPINT2 is critically required for the cell surface matriptase localization in Caco2 intestinal epithelial cells.
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HAI-1/SPINT1 AND HAI-2/SPINT2: EMERGING GUARDIANS OF EPITHELIAL INTEGRITY
We analyzed the expression and localization of HAI-1/SPINT1 protein in systemic organs using mouse monoclonal antibody specific for human HAI-1/SPINT1. This investigation revealed that HAI-1/SPINT1 is expressed in most epithelial cells throughout the body, although normal hepatocytes do not express HAI-1/SPINT1. 59 In polarized columnar epithelial cells, it localized primarily within the basolateral surface. 59 Placental cytotrophoblasts also expressed HAI-1/SPINT1 abundantly (Fig. 4a ), serving as a reliable surface marker to detect and isolate cytotrophoblasts. [60] [61] [62] To search for in vivo functions of HAI-1/SPINT1, we generated several Spint1-mutant mouse models. Global Spint1 knockout mice were embryonic lethal due to impaired formation of the placental labyrinth, 63 and the rescue of the placenta by a knockout chimera strategy allowed us to rear Spint1 À/À pups. 64 However, the Spint1 À/À neonates died within 16 days of birth, showing abnormal epidermal keratinization, cuticle defect in hair and whiskers, decreased barrier function of the skin and dermal inflammation (Fig. 4b) . 64, 65 The disturbance of epidermal integrity by Hai-1/Spint1 deficiency was also reported in a zebrafish mutant model. 66 Therefore, HAI-1/SPINT1 is critically required for the branching morphogenesis of the placenta and also has an indispensable role in normal epidermal integrity of the skin. Interestingly, these phenotypes were primarily caused by a dysregulated matriptase activity. Co-deletion of the St14 gene (encoding matriptase) in Spint1 KO mice wholly rescued placental development. 67 Mutant mice that showed markedly reduced matriptase activity (matriptase hypomorphic mice) did not exhibit Hai-1/Spint1 deficiency-induced skin phenotypes, 68 and the epidermal phenotype of zebrafish with Hai-1/Spint1 inactivation was alleviated by matriptase silencing. 66 On the other hand, whereas HAI-1/SPINT1 is highly expressed in intestinal epithelial cells in both humans and mice, intestine-specific deletion of the Spint1 gene (Spint1 LoxP/LoxP -Villin/Cre mice) did not cause significant morphological abnormalities in the intestinal epithelium. However, mice with a Spint1 À/À intestine were more susceptible to experimental colitis induced by dextran sodium sulfate (DSS) (Fig. 4c) . 69 More importantly, the absence of Hai-1/Spint1 in intestinal epithelial cells resulted in enhanced tumor susceptibility in an inflammation-associated colon carcinogenesis model. 70 HAI-2/SPINT2 is also broadly expressed in epithelial tissues and trophoblasts; however, its subcellular localization is still a matter of debate. Immunohistochemically and also immunocytochemically, HAI-2/SPINT2 is detected primarily in the cytoplasm (Figs. 3b, 4a) . 57, 71 Moreover, evidence suggests that HAI-2/SPINT2 localizes predominantly in the endoplasmic reticulum, 57 as opposed to the basolateral cell surface localization of HAI-1/SPINT1. Therefore, whereas HAI-1/SPINT1 and HAI-2/SPINT2 have homologous Kunitz domains with shared target proteases and are frequently coexpressed in the same cell, each HAI likely has a distinct function that cannot be compensated by the other. In fact, both Spint1 À/À mouse and Spint2 À/À mouse are embryonic lethal. 63, 72 The lethality of the Spint2 À/À embryo was caused by a gastrulation defect, neural tube closure defect, and impaired development of the placenta. 72 The precise physiological functions of HAI-2/SPINT2 in epithelial cells remain to be elucidated. Nonetheless, it is known that mutations of the SPINT2 gene are responsible for syndromic-form congenital sodium diarrhea, 73 indicating that HAI-2/SPINT2 has a major role in the intestinal epithelium in vivo. Of note, patients with the syndromic-form of congenital sodium diarrhea due to SPINT2 mutation show histopathological abnormalities consistent with those of congenital tufting enteropathy that is typically observed in mutation of the EPCAM gene encoding epithelial cell adhesion molecule (EpCAM). 74 Furthermore, in vitro study has indicated that dysfunction of HAI-2/SPINT2 results in matriptase-mediated EpCAM cleavage in Caco-2 human intestinal epithelial cells. 75 Thus, HAI-2/SPINT2 may maintain the integrity of intestinal epithelium through regulation of the matriptase activity and EpCAM turnover. Indeed, we observed that HAI-2/SPINT2 is required for normal localization of matriptase through regulation of the prostasin activity in intestinal epithelial cells, and insufficient HAI-2/SPINT2 enhanced shedding of active matriptase (Fig. 4d) . 41 Analysis using a conditional knockout mouse system for the Spint2 gene would clarify this hypothesis, which is currently under investigation in our laboratory. All of the evidence described above indicates that HAI-1/SPINT1 and HAI-2/SPINT2 are required for the integrity of the epidermis and intestinal epithelium through tight regulation of cellular TTSPs, particularly matriptase (Fig. 4d) . The skin and intestinal mucosal surface areas represent the most significant anatomic and physiologic portal for systemic exposure to environmental toxins and microorganisms, and the epithelial barrier protects the systemic compartment from these vulnerabilities. Consequently, insufficiency of HAIs may lead not only to unanticipated proteolytic activation of proHGF/SF and other bioactive molecules but also to epithelial barrier dysfunction that contributes to local and systemic diseases, including malignancies.
INSUFFICIENT HAI-1/SPINT1 CONTRIBUTES TO EPITHELIAL CARCINOGENESIS AND MALIGNANT PROGRESSION
Under conditions of uncontrolled or aberrant activation, HGF/SF-MET signaling drives neoplastic transformation, progression and metastasis in a broad spectrum of human malignancies. MET behaves as a driver oncogene in a minority of cancers in which constitutive MET signaling for tumor cell growth and survival is established by gene amplification or mutations. 8 However, in most cancers, tumor cells exploit the program triggered by wild-type MET, which relies on the ligand HGF/SF, as an expedient to confer malignant phenotypes. 8 Indeed, the HGF/SF-MET pathway sustains invasive growth, protects against apoptosis, promotes tumor cells' drug resistance and contributes to maintaining the cancer stem cell-like phenotype. 5, 8, Therefore, in transformed cells with wild-type MET, pericellular processing of proHGF/SF by HGFA or TTSP has critical significance in MET-dependent malignant progression. Moreover, some TTSPs also contribute to malignant progression through activation of other peptide growth factors, protease zymogens, and PAR-2 ( Table 2) . For example, transgenic matriptase expression in keratinocytes under control of the keratin 5 promoter induced squamous cell carcinoma of the skin in mice. 76 This phenomenon is mediated by MET-AKT-mTOR signaling initiated by matriptase-mediated proHGF/SF activation 77 and Gai-NFkB signaling induced by matriptase-mediated activation of PAR-2 in keratinocyte stem cells. 78 Moreover, matriptase confers progression of established squamous cell carcinomas by recruitment of cancer-associated fibroblasts through activation of fibroblast PAR-2. 79 In accordance with these observations, high matriptase levels in head and neck squamous cell carcinoma predict poorer prognosis of the patients. 80 The type I transmembrane architecture, tissue distribution and cell surface localization of HAI-1/SPINT1 ensure regulation of its target protease activity in the pericellular microenvironment in local epithelial tissues and tumors. Consequently, insufficient levels of HAI-1/SPINT1 on the surface of normal or transformed epithelial cells result in dysregulated activities of proHGF/SF-activating serine proteases. Indeed, autoactivation of matriptase occurs in an acidic environment, which is frequently observed in tumor tissues. 81, 82 This situation leads to sustained pericellular activation of proHGF/SF and other bioactive molecules. Moreover, HAI-1/SPINT1 insufficiency in epithelial cells induces barrier dysfunction and inflammation that may also promote neoplastic transformation. Therefore, it is conceivable that HAI-1/SPINT1 could serve as a tumor suppressor in epithelial tissues. Indeed, above described matriptase-induced skin carcinogenesis was suppressed by the forced overexpression of Hai-1/Spint1 in keratinocytes. 76 Overexpression of hepsin in mammary epithelial cell organoids down-modulated cell surface HAI-1/SPINT1, which in turn conferred oncogenicity of the cells by augmented HGF/SF signaling and disrupting epithelial cohesion. 83 The suppressive role of HAI-1/ SPINT1 in epithelial carcinogenesis was also confirmed using a loss of function model. The intestinal epitheliumspecific Spint1 KO mouse with an Apc gene mutation (Spint1 floxed/floxed /Villin-Cre/Apc Min/þ ) showed significantly increased polyp formation compared with control Spint1 floxed/floxed /Apc Min/þ mice, accompanying enhanced HGF/SF activation and increased NF-kB signaling. 70, 84 The increased tumor susceptibility associated with Spint1 deletion was also observed in a DSS colitis-associated colon carcinogenesis model, which implies a novel link between an epithelial cell surface protease inhibitor and protection from carcinogenic stimuli. 70 Therefore, HAI-1/SPINT1 is a tumor suppressor in certain epithelial malignancies. Our immunohistochemical studies have revealed that cellular HAI-1/SPINT1 is frequently decreased in carcinoma cells in the gastrointestinal tracts (Fig. 5a,b) . 29, 85 This is also the case for mouse intestinal tumors induced by an Apc mutation. 70 In oral squamous cell carcinoma cells, infiltrating cancer cells at the invasion front showed markedly decreased cell surface HAI-1/SPINT1 compared with those showing an expansive growth pattern (Fig. 5c ). 86 In pancreatic ductal carcinoma tissues, HAI-1/SPINT1 was rather broadly positive in neoplastic cells; however, the cases having areas of reduced HAI-1/SPINT1 immunoreactivity showed shorter disease-free survival. 87 The reduction of cell surface HAI-1/SPINT1 can be caused either by decreased transcription of the SPINT1 gene, posttranscriptional modulation by microRNA, or enhanced shedding of cell surface HAI-1/SPINT1 in cancer cells. Reduced transcription of the SPINT1 gene has been reported in a subset of non-small cell lung carcinoma cells and prostatic carcinoma cells via promoter hypermethylation or a mutant transcription factor (TMPRSS2/ERG fusion protein), respectively. 88, 89 It was suggested that microRNA (miR-221/222)-mediated suppression of HAI-1/SPINT1 expression in gastric adenocarcinoma cell lines accompanied increased HGFA expression. 90 Enhanced HAI-1/SPINT1 shedding was reported in colon cancers. 85 Evidence indicates that metalloproteases are responsible for the shedding of HAI-1/SPINT1, 55 and in carcinoma cells, membrane type-1 matrix metalloprotease (MMP14) and MMP7 are likely involved in the shedding (Fig. 3a) . 70, 91, 92 The cleaved fragment of HAI-1/SPINT1 induces homotypic tumor cell aggregation in the presence of MMP7, which in turn may support metastatic spreading of the cells. 92 Moreover, TTSP may also cleave HAI-1/SPINT1 if they are overexpressed. For example, induced hepsin overexpression in mammary epithelial cells markedly decreased cell surface HAI-1/SPINT1 due to the ectodomain cleavage by the excess hepsin activity.
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HAI-1/SPINT1 SUPPRESSES THE EPITHELIAL TO MESENCHYMAL TRANSITION (EMT)
Most evidence shows that reduced levels of HAI-1/SPINT1 in carcinoma cells lead to enhanced invasiveness and metastasis (Fig. 5d) . 12, 86, [93] [94] [95] In fact, relationship between the reduced HAI-1/SPINT1 and a poorer clinical outcome of gynecological, mammary, prostatic, oral and pancreatic ductal carcinomas have been reported. 12, 86, 87, [96] [97] [98] Of particular interest was the link between the level of HAI-1/SPINT1 and EMT. We examined a highly metastatic subline of the SUIT2 human pancreatic carcinoma cell line (S2-CP8). The cells had an EMT phenotype and showed markedly decreased expression of SPINT1 mRNA. 93 Forced expression of HAI-1/SPINT1 in S2-CP8 reverted E-cadherin expression (i.e., mesenchymal to epithelial transition). Consequently, silencing of the SPINT1 gene in the parental SUIT2 cells reduced E-cadherin expression with a morphology compatible with EMT through upregulation of ZEB2 (SIP1: Smad-interacting protein 1). 93 This phenomenon was likely mediated by dysregulated TMPRSS4, a member of the TTSP family, and matriptase may also be partly involved. 93 Indeed, TMPRSS4 was initially identified in an invasive subline of SUIT2 cells under the name "TMPRSS3", and its mRNA was overexpressed in pancreatic cancer. 99 TMPRSS4 reportedly promoted the EMT in the SW480 human colon carcinoma cell line. 100 However, the physiological substrates and precise function of TMPRSS4 remain to be clarified. A similar link between HAI-1/SPINT1 insufficiency and EMT was reported in both endometrial carcinoma cells and oral squamous cell carcinoma cells. 86, 98 In a prostate cancer model using immortalized human prostatic epithelial cells, overexpression of the TMPRSS2/ ERG fusion gene repressed SPINT1 expression, which subsequently upregulated ZEB2 expression contributing to the EMT phenotype of the cells. 89 Moreover, the SPINT1 gene was epigenetically silenced in a series of human non-small cell lung carcinoma cell lines that showed an EMT phenotype. 88 These lines of evidence indicate that HAI-1/SPINT1 is a suppressor of EMT. This notion is consistent with the observation that the expression of HAI-1/SPINT1 is a phenotype of terminally differentiated epithelial cells.
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The SPINT2 gene is epigenetically silenced in certain malignancies SPINT2 gene expression is markedly downregulated by hypermethylation in several malignancies, including glioblastoma, hepatoma, renal cell carcinoma and melanoma. [102] [103] [104] [105] [106] Reversion of HAI-2/SPINT2 in these cancer cells suppressed invasive growth, suggesting a tumor suppressor function of HAI-2/SPINT2. Indeed, the epigenetic silencing of SPINT2 has been reported in other cancer types, such as esophageal squamous cell carcinoma and gastric adenocarcinoma. 107, 108 On the other hand, the SPINT2 gene was initially reported as a pancreatic cancerassociated gene under the name of Kop (Kunitz domaincontaining protein overexpressed in pancreatic cancer). 109 In colon cancer, SPINT2 mRNA levels were unchanged in cancer tissue compared with the corresponding normal mucosa. 110 In breast cancer, high SPINT2 expression levels were observed in HER2-positive tumors, and high expression predicted a poor clinical treatment response rate. 111 Therefore, the roles for HAI-2/SPINT2 in cancers may be cell type-or tissue type-specific and might depend on the type of target protease(s) coexpressed in the same cells, which will require further investigations.
CONCLUSIONS AND FUTURE PERSPECTIVES
In this review, we summarized the mechanisms of pericellular proteolytic activation of HGF/SF and the homologous protein, MSP. We also introduced emerging regulatory roles of a membrane-anchored inhibitor of HGF/SF activation, namely HAI, in epithelial homeostasis and neoplastic progression (Figs. 4d,5d ). In the two decades following the discovery of HAI-1/SPINT1 and HAI-2/SPINT2, research has shown that there is a novel association between pericellular proteolysis and maintenance of epithelial integrity regulated by HAIs. The accumulated evidence described in this review indicates that both HAIs are guardians of epithelial integrity through regulation of HGFA, TTSPs and prostasin. Dysfunction of HAIs induces dysregulated pericellular proteolysis, uncontrolled activation of PAR-2, growth factors such as HGF/SF and disturbance of epithelial barrier function. The possibility of targeting the HGF/SF-MET pathway in cancer cells is a promising option, 5, 8 and the proHGF/SF activation step may serve as an attractive target. 12 We believe that the dual activation systems mediated by the circulating activator (HGFA) and cell surface activators (matriptase, hepsin, and other TTSPs) must be targeted to efficiently inhibit undesirable activation of proHGF/SF in the tumor microenvironment. This is also the case for the MSP-RON signaling pathway that also confers a malignant phenotype. 27 Moreover, TTSPs also contribute to cancer progression through mechanisms independent of their proHGF/SF-processing activity and thus, targeting TTSPs might have additional therapeutic benefits. 3 As all these proteases are inhibited by KD1 of HAI-1/SPINT1, use of recombinant KD1 may be a promising approach. In fact, KD1 suppresses the metastatic spreading of cancer cells in mouse models. 112, 113 Moreover, structural analysis of the complexes of KD1 and HGF/SF-activating proteases may have significant implications for the development of synthetic chemicals that specifically inhibit proteolytic activation of HGF/SF and MSP. To date, several promising small molecular weight compounds that specifically inhibit the HGF/SF-activating proteases have been reported. [114] [115] [116] [117] Generation of neutralizing antibodies against these proteases may also be a useful approach. Interestingly, a specific antibody acting as an allosteric inhibitor of catalytic activity that binds at the periphery of the substrate binding site of HGFA has been reported. 23 This allosteric inhibition mechanism may have implications for the development of innovative strategies to regulate HGF/SF-activating TTSPs possibly involved in cancer progression. 
